Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

3096 results about "Quantitative assay" patented technology

Assay - a quantitative or qualitative test of a substance (especially an ore or a drug) to determine its components; frequently used to test for the presence or concentration of infectious agents or antibodies etc.

System and method of measuring disease severity of a patient before, during and after treatment

A system and method of obtaining serial biochemical, anatomical or physiological in vivo measurements of disease from one or more medical images of a patient before, during and after treatment, and measuring extent and severity of the disease is provided. First anatomical and functional image data sets are acquired, and form a first co-registered composite image data set. At least a volume of interest (ROI) within the first co-registered composite image data set is identified. The first co-registered composite image data set including the ROI is qualitatively and quantitatively analyzed to determine extent and severity of the disease. Second anatomical and functional image data sets are acquired, and form a second co-registered composite image data set. A global, rigid registration is performed on the first and second anatomical image data sets, such that the first and second functional image data sets are also globally registered. At least a ROI within the globally registered image data set using the identified ROI within the first co-registered composite image data set is identified. A local, non-rigid registration is performed on the ROI within the first co-registered composite image data set and the ROI within the globally registered image data set, thereby producing a first co-registered serial image data set. The first co-registered serial image data set including the ROIs is qualitatively and quantitatively analyzed to determine severity of the disease and/or response to treatment of the patient.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection

Processes are disclosed using the depolymerization of a nucleic acid hybrid and incorporation of a suitable nucleotide to qualitatively and quantitatively analyze for the presence of predetermined nucleic acid target sequences. Applications of those processes include the detection of single nucleotide polymorphisms, identification of single base changes, genotyping, medical marker diagnostics, mirosequencing, and.
Owner:PROMEGA

Homogeneous fluorassay methods employing fluorescent background rejection and water-soluble rare earth metal chelates

Homogeneous assays for determining quantitatively the extent of a specific binding reaction can be carried out effectively on very dilute solutions using measurements of fluorescence if a fluorescence measurement scheme that is capable of rejecting short-lived background fluorescence is employed and if the fluorescent group being measured has the following properties: a. the group being measured must be a rare earth metal chelate complex combination; b. the chelate must be water-soluble; c. the complex combination must also be stable in extremely dilute aqueous solutions, that is, the measured chelate must have at least one ligand having a metal-to-ligand binding constant of at least about 1013M-1 or greater and it must have a fluorescent emission that is long-lived compared to the longest decay lifetime of ambient substances and have a half life of from 0.01 to 50 msec.
Owner:EG&G WALLAC

Qualitative and quantitative analytical modeling of sales performance and sales goals

InactiveUS20140324521A1Facilitate business risk analysisFinanceForecastingRisk profilingDecision taking
The present invention is applicable in the field of sales performance management coupled with corporate finance, corporate capital investments, economics, math, business risk analysis, simulation, decision analysis, qualitative risk analysis, risk management, quantitative risk analysis, and business statistics, and relates to the modeling and valuation of investment decisions and sales performance management and analysis under uncertainty and risk within all companies, allowing these firms to properly identify, assess, quantify, value, diversify, and hedge their corporate capital investment and sales management decisions and their associated risks. Specifically, the present invention looks at starting from comprehensive qualitative sales performance management and moving the analysis into the realms of quantitative risk-based sales performance modeling, simulation, and optimization.
Owner:MUN JOHNATHAN

Affinity-shifted probes for quantifying analyte polynucleotides

Compositions, methods and devices for detecting and quantifying levels of an analyte polynucleotide in homogeneous assays using collections of soluble or immobilized hybridization probes. In certain preferred embodiments, the probes are immobilized in an array format. Polynucleotides may be quantified directly, or amplified in an in vitro nucleic acid amplification reaction prior to detection and quantitation. Amplification reactions may be performed in contact with the invented probes, and analyte amplicons quantified in real-time or end-point assays.
Owner:GEN PROBE INC

Methods and systems for analyzing images of specimens processed by a programmable quantitative assay

Disclosed are methods and systems for analyzing images of specimens processed by a programmable quantitative assay or more specifically a robust programmable quantitative dot assay, PDQA, that enable specimens to be imaged and assessed across a wide variety of conditions and applications. Specific embodiments directed to immunohistochemical applications provide more quantitative methods of imaging and assessing biological samples including tissue samples.
Owner:AGILENT TECH INC

Full-automatic fluorescent quantitative immunity analyzer and detection method

ActiveCN105572407AProcessing supportRealize fully automated detection and analysisMaterial analysisFluorescenceData acquisition
The invention relates to a full-automatic fluorescent quantitative immunity analyzer and a method, and belongs to the technical field of detection. The full-automatic fluorescent quantitative immunity analyzer comprises a sample feeding device, a hatching device, a sampling device, a data acquisition device, a reagent card device and a system control module; the purpose of automatic quantitative immunity analysis is achieved through organic combination of all the devices and modules and mutual cooperation of all elements. According to the fluorescent quantitative immunity detection method, the full-automatic fluorescent quantitative immunity analyzer is adopted, therefore, full-automatic instrumental analysis is achieved, the detection efficiency is improved, and the professional requirement on an operator is lowered.
Owner:GUANGZHOU WONDFO BIOTECH

Device for simultaneously carrying out blood group determination, serum cross-check and antibody detection test

This invention relates to a device for the simultaneous qualitative or quantitative determination of several analytes in a liquid sample. The device comprises a membrane with a charging zone, for the application of the liquid sample, at least two indicator zones which can interact with the analyte(s) and at least one absorption region, which accepts the fluid after passing through the indicator zones, whereby the indicator zones lie between the charging zone and an absorption region, characterized in that the flow directions (flow tracks) are essentially parallel from the application zone through each indicator zone to an absorption region and at least two different flow tracks are present. The invention further relates to a method for the determination of several analytes or derivatives thereof in a liquid sample, comprising: application of the sample to the charging zone of a membrane of the device, whereby said sample is present in sufficient amounts to permit the sample fluid to flow in the direction of the absorption region through the indicator zones and to permit the analytes or derivatives thereof in the liquid sample to form a complex in the indicator zone.
Owner:GRIFOLS DIAGNOSTIC SOLUTIONS INC

Quantitative assay for low abundance molecules

A method for quantitatively assaying one or more target molecules in a sample uses a nucleic acid aptamer that is specific for each target molecule. A quantitative replicative procedure is used to determine a quantity of aptamer specific for each molecule.
Owner:SOURCE PRECISION MEDICINE INC

Hybrid phase lateral flow assay

ActiveUS20050227371A1Increased binding surface areaHigher irreversible immobilizationCompound screeningApoptosis detectionAnalyteReagent
The invention relates to devices for performing single step assays for the determination of the presence or absence of an analyte in a liquid sample, and methods of determining the presence or absence of such analytes using such devices. Devices disclosed comprise a labeled analyte-binding reagent reversibly-immobilized on a non-porous solid material, which solid material is in physical contact with a dry porous carrier bearing an immobilized analyte-binding reagent. Also provided are quantitative assay devices.
Owner:QUIDEL

Matrix for receiving a tissue sample and use thereof

A custom-made matrix suitable for receiving a tissue sample is described as well as the use thereof to obtain a multiplex histological preparation. The invention also relates to a multiplex biopsy array comprising tissue and / or cell samples arranged in a matrix material and to a method for the preparation of a multiplex biopsy array. Methods for preparing blocks of matrix material to be used in multiplex biopsy arrays are also described, as well as methods for loading biopsy samples in said blocks, and methods for treating and processing said blocks to form biopsy arrays. The biopsy arrays made using the block of matrix material can be used to prepare sections and slides for histological procedures, including quantitative analyses and parallel processing.
Owner:LEAVITT MEDICAL +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products